Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.
about
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesAnti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasomeBiologics registers in RA: methodological aspects, current role and future applications.Usability of an innovative and interactive electronic system for collection of patient-reported data in axial spondyloarthritis: comparison with the traditional paper-administered format.Ten years with biologics: to whom do data on effectiveness and safety apply?Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey.Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity.Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature.Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.The significance of presenteeism for the value of lost production: the case of rheumatoid arthritis.Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study.Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis.DANBIO--powerful research database and electronic patient record.Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Does disease activity at start of biologic therapy influence work-loss in RA patients?Segmentation of joint and musculoskeletal tissue in the study of arthritis.Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.Does disease activity at the start of biologic therapy influence health care costs in patients with RA?Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.'Rheumatologist go home!' Coming up next?Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.[The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].A prospective study of anti-tumor necrosis factor therapy in South African rheumatoid arthritis patients.Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.[Treat to target and personalized medicine (precision medicine)].A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences
P2860
Q26778600-5F966721-7D38-47FC-9682-678999E2C64EQ28540052-92EA6228-D40C-4872-8AE1-570D0D72693EQ30234303-5887F0A5-E643-4C92-9C64-59E8ACD24436Q30662141-C500F895-88DB-4089-890C-DE6DFF952F08Q33749195-12C473FA-4827-44CC-9F77-14F76E09AAC0Q33883662-7671A3AF-152A-4592-B4DB-C684D01CA2B3Q34027422-0B67F04E-E0AF-474E-979B-9006B1893495Q34156535-B7B04098-12B1-4373-BC51-0B061332512EQ34395306-A3527D0A-9022-4685-825D-F373D79C4E61Q34601527-84D10020-1044-47DF-BD17-7F8FAA747BCCQ35048347-9517497D-07C7-4559-9C78-36BBE047288EQ35205360-C0CA30FF-BA1E-490A-9DAD-E7D79CFD4B1EQ35986249-6E7BD495-6CC7-4D89-AE97-39922BDA3CFAQ36081041-D842214B-3B76-4125-AA11-BD8C6F1CEFD1Q36603266-1E0B8DD7-B4FA-45E6-9E6F-11E149C12692Q37034034-154541AB-2EE3-4C57-95C9-1DD266345A72Q37473766-6482D293-E4F0-44B5-83A0-1DE71DE5A83EQ37728019-B57DDF63-5E9E-4554-B7AC-D83DC6FA7EFAQ37819496-987DFB8F-ADC5-4743-A476-6233064682CFQ38305522-0FC9893C-EB0E-440F-A79B-31E3AE8EEBA7Q38410704-FFC3DA31-23BA-4AA4-802E-7D64C218FF78Q38750009-4A2EBFB9-3078-419B-93D4-7C8602F901A8Q40314992-2D092BDA-729F-4607-ADB5-F7B8F0CC3103Q40735887-8C9C3950-4B55-4F53-B2DC-F3CF3F9F7088Q41183360-CA8A9C19-2CB6-42BF-A562-F93E9CD929E3Q42210089-395BAFFE-5D5E-4550-9889-F788A7E323EBQ43689633-11606859-600B-4FFD-A6B8-7757AF54D323Q44376708-6008FF8F-0E1D-450F-80C9-3D45532FC7E1Q45229094-21ECCBB0-56D5-476B-9C58-724DE572CB29Q45790066-D2A45DF4-8348-4EBA-AA4C-40027D30EA88Q45950373-107593A8-EADA-4517-8DFF-34A89CB180A9Q46326827-531716E7-1A6E-4933-B9F6-2FFE11868697Q46893265-7B2B6505-D9A2-4A25-A1EA-163D8EC07FFDQ47272022-FF2DA861-C1AF-4912-B512-5B78C844E9ACQ50553120-84A9D826-3EB3-442F-A1FA-FF2EC501B34FQ50591145-337F3FA0-DACC-4628-A653-EC5AF367AE56Q51006503-BAEE72BB-0B71-4A01-BFE8-3132B6937D5CQ52850371-ECD503CD-B0EA-46A3-B2FB-79E6650F365EQ58800375-C3FC8C2A-624C-4BA6-91DF-A80F841711E8
P2860
Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Do changes in prescription pra ...... onwide Danish DANBIO Registry.
@en
Do changes in prescription pra ...... onwide Danish DANBIO Registry.
@nl
type
label
Do changes in prescription pra ...... onwide Danish DANBIO Registry.
@en
Do changes in prescription pra ...... onwide Danish DANBIO Registry.
@nl
prefLabel
Do changes in prescription pra ...... onwide Danish DANBIO Registry.
@en
Do changes in prescription pra ...... onwide Danish DANBIO Registry.
@nl
P2093
P356
P1476
Do changes in prescription pra ...... ionwide Danish DANBIO Registry
@en
P2093
J Pødenphant
J Unkerskov
M Østergaard
V S Ringsdal
P304
P356
10.1136/ARD.2007.087262
P407
P577
2008-02-13T00:00:00Z